Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Header
News Archive
Showing 1233 results
August 2017
-
Press Release
Novartis Kisqali® (ribociclib) receives EU approval as first-line treatment for HR+/HER2- locally advanced or metastatic breast cancer in combination with any aromatase inhibitor
Approval is based on pivotal MONALEESA-2 trial, which showed Kisqali plus letrozole reduced risk of disease progression or death by 43% versus letrozole alone[1] Kisqali plus letrozole… -
Press Release
Novartis et Medicines for Malaria Venture lancent une étude clinique en Afrique pour KAF156, un candidat-médicament novateur contre le paludisme multirésistant
Ce candidat-médicament pourrait s'avérer déterminant dans la lutte contre le paludisme en éliminant rapidement l'infection paludéenne, y compris les souches résistantes et en bloquant la… -
Press Release
Novartis and Medicines for Malaria Venture launch patient trial in Africa for KAF156, a novel compound against multidrug-resistant malaria
Compound has potential to be a game-changer in malaria elimination, rapidly clearing malaria infection, including resistant strains, and blocking parasite transmission KAF156 is first… -
Press Release
Novartis und Medicines for Malaria Venture starten in Afrika eine Patientenstudie mit KAF156, einem neuartigen Wirkstoff gegen multiresistente Malaria
Der Wirkstoff führt zu rascher Parasitenfreiheit auch bei resistenten Erregerstämmen, blockiert die Übertragung der Erreger und könnte damit eine Wende im Kampf gegen Malaria herbeiführen.…
July 2017
-
Press Release
Sandoz expands partnership with World Child Cancer, to help children access treatment in four developing countries
Expanded partnership to help "even the odds" of survival for children with cancer in the Philippines, Myanmar, Mexico and Ghana In developed countries, the survival rate for childhood cancer is… -
Press Release
Novartis receives positive CHMP opinion for Rydapt® (midostaurin) for newly diagnosed FLT3-mutated acute myeloid leukemia (AML) and three types of advanced systemic mastocytosis (SM)
Recommendation based on largest trial in FLT3-mutated AML to date, showing 23% reduction in the risk of death with Rydapt treatment regimen[1] If approved, Rydapt would represent the first… -
Press Release
Die Ergebnisse im zweiten Quartal bestätigen die Jahresprognosen - starke Forschungs- und Entwicklungsresultate untermauern das Potenzial einiger hoch innovativer Produkte
Der Nettoumsatz liegt auf Vorjahresniveau (0% kWk[1], -2% USD), wobei die Wachstumstreiber die Einbussen durch Generika von Glivec/Gleevec wettmachen: Cosentyx (USD 490 Millionen, +90% kWk)… -
Press Release
Les résultats du T2 confirment les prévisions de l'exercice 2017. Les très bons résultats du pipeline étayent le potentiel de plusieurs produits hautement novateurs
Chiffre d'affaires net comparable à celui du T2 de l'exercice précédent (0% tcc[1], -2% en USD), car les moteurs de croissance ont compensé l'impact des génériques de Gleevec/Glivec: Cosentyx (… -
Press Release
Q2 results confirm full year guidance. Strong pipeline results underpin potential of several highly innovative products
Net sales in line with prior year (0% cc[1], -2% USD), as growth drivers offset Gleevec/Glivec Gx impact: Cosentyx (USD 490 million, +90% cc) continues strong growth in all three indications… -
Press Release
Novartis confirms 5 year data for first and only fully-human IL-17A inhibitor Cosentyx® reinforcing sustained efficacy and safety profile in psoriasis
5 year data from long-term Phase III extension study demonstrate sustained efficacy and safety of Cosentyx in patients with moderate-to-severe plaque psoriasis[1] Data planned to be… -
Press Release
Novartis CAR-T cell therapy CTL019 unanimously (10-0) recommended for approval by FDA advisory committee to treat pediatric, young adult r/r B-cell ALL
Recommendation based on review of CTL019 r/r B-cell ALL development program, including the pivotal Phase II global ELIANA trial A Biologics License Application (BLA) for this indication is… -
Press Release
Novartis receives approval in the EU for Cosentyx label update, includes long term superiority data versus Stelara in psoriasis
Label update includes 52 week data from CLEAR study demonstrating long-term superiority of Cosentyx® versus Stelara® in psoriasis [1],[2] Update also includes use of Cosentyx in moderate-to…